



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/12, 15/00, A01N 43/04, C07H 21/02	A1	(11) International Publication Number: WO 98/36055 (43) International Publication Date: 20 August 1998 (20.08.98)
(21) International Application Number: PCT/US98/02249 (22) International Filing Date: 5 February 1998 (05.02.98) (30) Priority Data: 08/799,144 13 February 1997 (13.02.97) US (71) Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY [US/US]; 1300 Morris Park Avenue, Bronx, NY 10461 (US). (72) Inventors: GELIEBTER, Jan; 1845 East 26th Street, Brooklyn, NY 11229 (US). MELMAN, Arnold; 23 Agnes Circle, Ardsley, NY 10502 (US). CHRIST, George, J.; 9 Mallard Lane, Smithtown, NY 11787 (US). REHMAN, Jamil; 3450 Wayne Avenue 22H, Bronx, NY 10467 (US). (74) Agents: GEORGE, Kenneth, P. et al.; Amster, Rothstein & Ebenstein, 90 Park Avenue, New York, NY 10016 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: GENE THERAPY FOR ALLEVIATING ERECTILE DYSFUNCTION		
(57) Abstract <p>The present invention is directed towards gene therapy for erectile dysfunction through delivery and expression of a recombinant vector containing a DNA sequence encoding a protein involved in the regulation of smooth muscle tone into a smooth muscle cell. Also provided by the present invention is a method of inducing penile erection in a subject comprising the introduction and expression of a DNA sequence encoding a protein involved in the regulation of smooth muscle tone into a sufficient number of cells of the subject to induce penile erection in the subject. The present invention also provides a recombinant vector comprising the DNA of or corresponding to at least a portion of the genome of a virus, which portion is capable of directing the expression of a DNA sequence, and DNA encoding a protein involved in the regulation of smooth muscle tone operably linked to the viral DNA and capable of being expressed as a functional gene product in the target cell. Also provided by the present invention is a smooth muscle cell which expresses a gene encoding a protein involved in the regulation of smooth muscle tone.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

GENE THERAPY FOR ALLEVIATING ERECTILE DYSFUNCTION

5

Background of the Invention

Erectile dysfunction is a common illness that is estimated to affect 10 to 30 million men in the United States (Feldman, et al. *Journal of Clinical Epidemiology* 47.5 (1994) 457-67; Anonymous, *International Journal of Impotence Research* 5.4 (1993) 181-284). Among the primary disease-related causes of erectile dysfunction are atherosclerosis, diabetes, aging, hypertension and antihypertensive medication, chronic renal disease, pelvic surgery and radiation therapy, and psychological anxiety (Feldman, et al. *Journal of Clinical Epidemiology* 47.5 (1994) 15 457-67). Direct cures for the vascular ravages of these manifold and multifaceted disease states are unlikely to occur in the near future, and thus, the last decade has witnessed the development of several treatment modalities to directly restore diminished erectile capacity. However, all currently available therapies are either non-specific (hormonal therapy), of limited overall success (e.g., vacuum erection 20 devices), invasive (e.g., intracorporal injection therapy) or non-reversible and expensive (e.g., penile prosthetic implant surgery). Despite these therapeutic limitations the recent FDA approval of *Caverject* (prostaglandin E₁) for the intracavernous treatment of erectile dysfunction represents a major step forward. In essence, this act of the Federal Government has resulted in both the formal 25 recognition of the medical nature of the problem, and furthermore, legitimized its clinical treatment.

Recent changes in contemporary cultural patterns in the United States have allowed for a free and more open public discussion of sex and sexual dysfunction. This cultural trend has both highlighted the magnitude of the problem, 30 and simultaneously emphasized the need for improved clinical treatment of erectile dysfunction. The recent deluge of advertising and media activity related to the discussion and treatment of the problem has made men, and their sexual partners more aware that erectile dysfunction is a common problem with legitimate (federally

-2-

approved) clinical treatments available. This combination of events will continue to promote even larger numbers of men to seek treatment for impotence from their physicians during the next decade. There is thus a need for a better understanding the impact of age and disease on human erection through the study of the function of the
5 corporal and arterial smooth muscle at the whole tissue, cellular, and most recently at the subcellular level. Also needed is a research strategy that will enable the direct translation of the results of laboratory work to the clinical environment, ensuring that new treatments for organic erectile dysfunction will be more cost effective, of greater efficacy and with fewer side effects.

10 Studies have documented that altered corporal smooth muscle tone, resulting in either heightened contractility or impaired relaxation, is a proximal cause of erectile dysfunction in a large proportion of impotent men. These studies have further indicated that complete relaxation of the corporal smooth muscle is both a necessary and sufficient condition to restore erectile potency, unless severe arterial
15 disease or congenital structural abnormalities exist; the latter is true in a minority of patients. The FDA approval of the intracavernous injection of the smooth muscle relaxant PGE₁ verifies the validity of this supposition.

As described above, the critical role played by the corporal smooth muscle cells in erectile function makes them an excellent target for molecular
20 intervention in the treatment of erectile dysfunction. Previous efforts have focused on techniques for gene transfer into vascular smooth muscle cells as a basis for the potential therapy of several cardiovascular diseases. Among these are atherosclerosis, vasculitis and restenosis after balloon angioplasty. These initial studies have provided important information on the efficiency and persistence of gene transfer methods in
25 smooth muscle cells (Finkel, et al. *FASEB Journal* 9 (1995) 843-51).

Thus, because erectile dysfunction is largely caused by altered smooth muscle tone, a method of gene therapy which targets the genes involved in the alteration of smooth muscle tone is extremely desirable. Further, of critical importance with respect to all *in vivo* gene therapy approaches is the percentage of
30 target cells that must be affected, and the relative efficiency of affecting only the

-3-

desired cell type(s) to see a physiologically relevant therapeutic effect. Accordingly, there is a need for a method of gene therapy wherein only a small number of cells would need to be genetically modified to affect global changes in tissue function. Finally, a successful method of gene therapy for alleviating erectile dysfunction is in
5 great demand as it would be a preferred alternative to currently used methods.

Summary of the Invention

The present invention is directed towards gene therapy for erectile dysfunction through delivery and expression of a recombinant vector containing a
10 DNA sequence encoding a protein involved in the regulation of smooth muscle tone into a smooth muscle cell.

The present invention specifically provides for a method of gene therapy wherein the DNA sequence that encoding a protein that is involved in the regulation of smooth muscle cells encodes a protein that regulates corporal smooth
15 muscle tone in a corporal smooth muscle cell by modulating vasorelaxation. These proteins will enhance corporal smooth muscle relaxation resulting in a more easily attained erection. Also contemplated is a method of gene therapy wherein the DNA sequence encodes a protein that inhibits vasoconstriction of a smooth muscle.

Also provided by the present invention is a method of inducing penile
20 erection in a subject comprising the introduction and expression of a DNA sequence encoding a protein involved in the regulation of corporal smooth muscle tone into a sufficient number of cells of a subject to induce penile erection in the subject. In the preferred embodiment, the method of gene therapy of present invention is used to alleviate erectile dysfunction.

25 The present invention also provides a recombinant vector comprising the DNA of or corresponding to at least a portion of the genome of a virus, which portion is capable of directing expression of a DNA sequence, and DNA encoding a protein involved in the regulation of corporal smooth muscle tone operably linked to the viral DNA and capable of being expressed as a functional gene product in the
30 target cell.

-4-

The present invention additionally provides for a smooth muscle cell, such as a corporal or arterial smooth muscle cell, that encodes a protein involved in the regulation of smooth muscle tone.

Additional objects of the invention will be apparent from the description 5 which follows.

Brief Description of the Figures

Figure 1: Figure 1 illustrates how selective blockade of the maxi-K channel alters the NTG-induced relaxation response in isolated human corporal tissue strips. A 10 modification of a previously published kinetic protocol was used (Christ, et al., *American Journal of Physiology* 263:H15-H19 (1992)) to derive two parameters; $\tau_{1/2}$: the time elapsed from addition of NTG to achievement of 50% of the steady-state relaxation response; RSS: the steady-state magnitude of the NTG-induced relaxation response. Note that preincubation of isolated corporal tissue strips resulted in a 15 significant reduction in the magnitude of the NTG-induced relaxation response (100 nM). PE=Phenylephrine; NTG=Nitroglycerine.

Figure 2: Figure 2 sets forth an illustration of K channel function and the control of corporal smooth muscle tone. K^+ ion flux is controlled by three main effector 20 pathways, the first two are the cAMP/PKA (PKA: protein kinase A) and cGMP/PKG (protein kinase G) pathways which are activated by PGE_1 and NO^- , respectively, and these pathways clearly modulate the activity of the maxi-K channel; their effects on the K_{ATP} channel have not been documented. The third pathway is the potassium channel modulators, which modulate the activity of the K_{ATP} channel. Because of the 25 disposition of these ions in the intra- and extracellular spaces, the opening of Ca^{2+} channels leads to the influx of Ca^{2+} down its electrochemical gradient and subsequent intracellular depolarization, while the opening of K channels leads to efflux of K^+ from the cell down its electrochemical gradient, and subsequent intracellular hyperpolarization. The effects of these reciprocal pathways on membrane potential 30 and the level of corporal smooth muscle tone are exerted, at least in part, through

-5-

modulation of the intracellular calcium concentration, with increases in intracellular calcium associated with contraction, and decreases in intracellular calcium associated with relaxation. (+) denotes a positive or stimulatory effect; (-) denoted a negative or inhibitory effect; ? denoted an unknown action; PIP_2 : phosphatidylinositol 5 biphosphate; DAG: diacylglycerol; IP_3 : inositoltrisphosphate; NO : nitric oxide; NTG: the nitrate donor nitroglycerin; ET-1: endothelin-1; PE: phenylephrine; L-type Ca^{2+} : L-type, voltage dependent calcium channel.

Figure 3: Figure 3 illustrates the surgical preparation and placement of pressure monitoring cannulae. As shown, the rat is anaesthetized and lying supine. The arterial line in the left carotid artery is connected to a MacLab data acquisition board via a transducer and transducer amplifier, for continuous monitoring of blood pressure. A right external jugular venous line is utilized for intravenous fluid transfusion or blood sampling. As shown, the prostate has been exposed by a lower midline incision. The cavernous nerves are seen on the posterolateral surface of the prostate arising from the pelvic ganglion which is formed by the joining of the hypogastric and pelvic nerves. The two corpora have been exposed by inguinoscrotal incisions on both sides, combined with degloving of the penis. A line is inserted into the right corpora for continuous monitoring of intracorporal pressure via the MacLab instrumentation. Yet another line is inserted in the left corpora for intracavernous drug injection. Lastly, the nerve stimulator probe is placed around the cavernous for current stimulation.

Figure 4: Figure 4 sets forth the results of experiments determining the fractional change in intracavernous pressure (ICP) in response to neurostimulation.

Figure 5: Figure 5 sets forth a diagram indicating the major mechanisms regulating corporal smooth muscle tone. Shown are two corporal smooth muscle cells, interconnected by a gap junction plaque at their lateral border. Also shown are voltage-dependent Ca channels, and K channels. The left cell depicts the series of

-6-

intracellular events linked to corporal smooth muscle contraction (an elevation in intracellular calcium levels), while the right depicts the series of intracellular events linked to corporal smooth muscle relaxation (a decrease in intracellular Ca^{2+} levels).

+: means a stimulatory, positive or increasing effect, and -: means a inhibitory or
5 negative effect

Detailed Description of the Invention

The present invention provides a method of gene therapy for erectile dysfunction through delivery and expression of a recombinant vector containing a
10 DNA sequence encoding a protein involved in the regulation of smooth muscle tone in a smooth muscle cell. The DNA sequence may be genomic DNA or cDNA.

The present invention further provides a method of gene therapy wherein the protein involved in the regulation of smooth muscle tone modulates vasorelaxation. Examples of proteins which modulate vasorelaxation include, for
15 example, nitric oxide synthase, guanylate cyclase, adenylate cyclase, protein kinase G, protein kinase A, potassium channels, calcium channels, and any combination thereof. These proteins will enhance smooth muscle relaxation resulting in a more easily attained erection

Also contemplated for use in the method of the present invention is a
20 DNA sequence that encodes a protein that acts to inhibit a protein that modulates vasoconstriction of smooth muscle. An example of a protein that modulates vasoconstriction of corporal smooth muscle is protein kinase C. Proteins which inhibit those proteins that are involved in the vasoconstriction of the smooth muscle cell will ultimately cause enhanced corporal smooth muscle relaxation and a more
25 easily attained erection; exerting their effects, at least in part, via decreases in intracellular Ca^{2+} levels and altered myofilament sensitivity.

Examples of smooth muscle cells for which the method of gene therapy may be used include, but are not limited to, corporal smooth muscle cells and arterial smooth muscle cells. Given the many histological and physiological similarities
30 between corporal smooth muscle cells and other vascular tissue, it follows naturally

-7-

that similar principles would apply to the arterial smooth muscle cells of the penis.

The DNA sequence may be introduced into the smooth muscle cell by a number of procedures known to one skilled in the art, such as electroporation, DEAE Dextran, monocationic liposome fusion, polycationic liposome fusion, 5 protoplast fusion, DNA coated microprojectile bombardment, by creation of an *in vivo* electrical field, injection with recombinant replication-defective viruses, homologous recombination, and naked DNA transfer. It is to be appreciated by one skilled in the art that any of the above methods of DNA transfer may be combined.

The present invention also provides a method of inducing penile 10 erection in a subject comprising the introduction and expression of a DNA sequence encoding a protein involved in the regulation of smooth muscle tone into a sufficient number of smooth muscle cells of the subject to induce penile erection in the subject. In a preferred embodiment, the method of the present invention is used to alleviate erectile dysfunction. The erectile dysfunction may result from a variety of disorders 15 including neurogenic, arteriogenic and veno-occlusive dysfunctions as well as other conditions which cause incomplete relaxation of the smooth muscle. The subject may be animal or human, and is preferably human.

The introduction of the DNA sequence into the cells of the subject may be effected by methods known to one skilled in the art, such as electroporation, 20 DEAE Dextran, cationic liposome fusion, protoplast fusion, by creation of an *in vivo* electrical field, DNA coated microprojectile bombardment, injection with recombinant replication-defective viruses, homologous recombination, and naked DNA transfer. It will be appreciated by those skilled in the art that any of the above methods of DNA transfer may be combined. In a preferred embodiment of the invention, DNA 25 transfer is the preferred method.

For the purposes of naked DNA transfer into smooth muscle cells, the recombinant vector of the present invention, which contains the gene for expression, may be combined with a sterile aqueous solution which is preferably isotonic with the blood of the recipient. Such formulations may be prepared by suspending the 30 recombinant vector in water containing physiologically compatible substances such as

-8-

sodium chloride, glycine, and the like, and having buffered pH compatible with physiological conditions to produce an aqueous solution, and rendering such solution sterile. In a preferred embodiment of the invention, the recombinant vector is combined with a 20-25% sucrose in saline solution in preparation for introduction into
5 a smooth muscle cell.

The recombinant vector of the present invention containing the DNA sequence for expression may also be incorporated into cationic liposomes and directly injected into the smooth muscle cells of the subject. In a preferred embodiment of the invention, the transfer of the DNA sequence encoding a protein involved in the
10 regulation of smooth muscle tone is by naked DNA transfer.

The present invention also provides a recombinant vector comprising (1) the nucleic acid of or corresponding to at least a portion of the genome of a virus, which portion is capable of directing the expression of a DNA sequence, and (2) a DNA sequence encoding a protein involved in the regulation of smooth muscle tone
15 operably linked to the viral nucleic acid and capable of being expressed as a functional gene product in the target cell. The recombinant viral vectors of the present invention may be derived from a variety of viral nucleic acids known to one skilled in the art, e.g. the genomes of HSV, adenovirus, adeno-associated virus, Semiliki Forest virus, vaccinia virus, and other viruses, including RNA and DNA viruses.

20 The recombinant vectors of the present invention also contain a nucleotide sequence encoding suitable regulatory elements so as to effect expression of the vector construct in a suitable host cell. As used herein, "expression" refers to the ability of the vector to transcribe the inserted DNA sequence into mRNA so that synthesis of the protein encoded by the inserted nucleic acid can occur. Those
25 skilled in the art will appreciate that a variety of enhancers and promoters are suitable for use in the constructs of the invention, and that the constructs will contain the necessary start, termination, and control sequences for proper transcription and processing of the DNA sequence encoding a protein involved in the regulation of smooth muscle tone when the recombinant vector construct is introduced into a host
30 cell.

-9-

Vectors suitable for the expression of the DNA sequence encoding a protein involved in the regulation of smooth muscle tone in a smooth muscle cell are well known to one skilled in the art and include pET-3d (Novagen); pProEx-1 (Life Technologies), pFastBac 1 (Life Technologies), pSFV (Life Technologies), pcDNA 5 II (Invitrogen), pSL301 (Invitrogen), pSE280 (Invitrogen), pSE380 (Invitrogen), pSE420 (Invitrogen), pTrcHis A,B,C (Invitrogen), pRSET A,B,C (Invitrogen), pYES2 (Invitrogen), pAC360 (Invitrogen), pVL1392 and pVl1392 (Invitrogen), pCDM8 (Invitrogen), pcDNA I (Invitrogen), pcDNA I(amp) (Invitrogen), pZeoSV (Invitrogen), pcDNA 3 (Invitrogen), pRc/CMV (Invitrogen), pRc/RSV (Invitrogen), 10 pREP4 (Invitrogen), pREP7 (Invitrogen), pREP8 (Invitrogen), pREP9 (Invitrogen), pREP10 (Invitrogen), pCEP4 (Invitrogen), pEBVHis (Invitrogen), and λ Pop6. Other vectors would be apparent to one skilled in the art.

Suitable promoters include, but are not limited to, constitutive promoters, tissue specific promoters, and inducible promoters. In one embodiment 15 of the invention, expression of the DNA sequence encoding a protein involved in the regulation of smooth muscle tone is controlled and affected by the particular vector into which the DNA sequence has been introduced. Some eukaryotic vectors have been engineered so that they are capable of expressing inserted nucleic acids to high levels within the host cell. Such vectors utilize one of a number of powerful 20 promoters to direct the high level of expression. Eukaryotic vectors use promoter-enhancer sequences of viral genes, especially those of tumor viruses. This particular embodiment of the invention provides for regulation of expression of the DNA sequence encoding the protein using inducible promoters. Non-limiting examples of inducible promoters include, but are not limited to, metallothionine promoters and 25 mouse mammary tumor virus promoters. Depending on the vector, expression of the DNA sequence in the smooth muscle cell would be induced by the addition of a specific compound at a certain point in the growth cycle of the cell. Other examples of promoters and enhancers effective for use in the recombinant vectors of the present invention include, but are not limited to, CMV (cytomegalovirus), SV40 (simian virus 30 40), HSV (herpes simplex virus), EBV (epstein-barr virus), retroviral, adenoviral

-10-

promoters and enhancers, and smooth muscle specific promoters and enhancers.

The present invention further provides a smooth muscle cell which expresses a DNA sequence encoding a protein involved in the regulation of smooth muscle tone. As used herein, "exogenous" means the DNA sequence is introduced 5 from outside the organism. The introduction of the recombinant vector containing the DNA sequence into the smooth muscle cell may be effected by methods known to one skilled in the art, such as electroporation, DEAE Dextran, cationic liposome fusion, protoplast fusion, DNA coated microprojectile bombardment, injection with recombinant replication-defective viruses, homologous recombination, and naked DNA 10 transfer. It will be appreciated by those skilled in the art that any of the above methods of DNA transfer may be combined.

Of critical importance with respect to all *in vivo* gene therapy approaches is the percentage of target cells that must be affected, and the relative efficiency of affecting only the desired cell type(s) to see a physiologically relevant 15 therapeutic effect. In this regard, there are two main reasons for suspecting that gene therapy of erectile dysfunction may be inherently more successful than its proposed uses in other, more systemic, cardiovascular disorders, such as those outlined above:

It is a well documented fact that corporal and arterial smooth muscle cells are interconnected by a ubiquitously distributed population of intercellular 20 channels known as gap junction proteins both *in vivo* and *in vitro* (Christ, G.J., et al. *Life Sciences* 49.24 (1991) PL195-200; Christ, G.J., et al. *International Journal of Impotence Research* 5.2 (1993) 77-96; Christ, G.J., et al. *Journal of Pharmacology & Experimental Therapeutics* 266.2 (1993) 1054-65; Christ, G.J., et al. *Biophysical Journal* 67.3 (1994) 1335-44; Christ, G.J., *Urological Clinic of North America*, 22.4. 25 (1995) 727-745; Christ, G.J. *World Journal of Urology* (1997) (in press); Christ, et al., *Circulation Research*, 79 (1996) 631-646; Christ & Melman, *Molecular Urology* (1997) (in press)), the mechanisms for which are depicted in Figure 5.

In the corpora, smooth muscle contraction (i.e. elevation in intracellular calcium levels) might be accomplished following activation of the α_1 -adrenergic

-11-

receptor by norepinephrine, or by endothelin-1 activation of the ET_A receptor. In both cases, receptor activation leads to Ca²⁺ mobilization. Specifically, activation of these receptors by norepinephrine or ET-1 leads to activation of phospholipase C, which cleaves membrane bound phosphatidyl inositol (PIP₂) into IP₃ and diacylglycerol (DAG). As illustrated in Figure 2, increases in DAG and IP₃ ultimately exert their effects, at least in part, via increase in intracellular Ca²⁺ levels. Conversely, any physiological event resulting in a diminution of transmembrane Ca²⁺ flux, or sequestration of intracellular Ca²⁺, e.g. membrane hyperpolarization, will result in smooth muscle relaxation. As such, PGE₁ activates the PGE₁ receptor, to stimulate the adenylate cyclase enzyme, which then catalyzes the conversion of ATP to cAMP. Increased cAMP then stimulates protein kinase A (PKA). Alternately, smooth muscle relaxation can be achieved by nitric oxide, released from endothelial or neuronal sources. Nitric oxide diffuses into smooth muscle cells to activate soluble guanylate cyclase, that catalyzes the conversion of GTP to cGMP. Elevated cGMP levels activate protein kinase G (PKG). The effects of PKA, PKG, and PKC on gap junctions, K channels, and Ca²⁺ channels are thought to be mediated via phosphorylation of specific amino acid residues on target proteins (gap junctions, K channels, and Ca²⁺ channels). Figure 5 illustrates the result of their putative actions as follows: +: means a stimulatory, positive or increasing effect, and -: means a inhibitory or negative effect. This simplified model illustrates how the interactions of these important second messenger systems might impact on gap junctions, K, and Ca²⁺ channels, and thus modulate corporal smooth muscle tone *in vitro* and *in vivo*.

Connexin43 is the predominant isoform expressed in the human penis. These intercellular channels provide partial cytoplasmic continuity between adjacent smooth muscle cells, allowing the intercellular exchange of physiologically relevant ions (K⁺ and Ca²⁺) and second messenger molecules (IP₃, cAMP, cGMP). This is an extremely important point given the relatively sparse autonomic innervation of the corporal parenchyma, even in the healthy male. Thus, the presence of gap junctions provides the anatomic substrate required for the rapid and syncytial contraction and relaxation responses required of the corporal smooth muscle cells for normal penile

-12-

erection, as well as detumescence. In this fashion, even in the healthy male, the presence of gap junctions allows smooth muscle cells not directly activated by a relevant neuronal signal to be rapidly, albeit indirectly, recruited into the contraction or relaxation response by this prominent intercellular pathway. The experimental and
5 clinical evidence verifying the validity of this supposition has been outlined in recent publications (Christ, G.J., et al., *Circulation Research*, 79:631-646 (1996); Christ, G.J., *World Journal of Urology*, (1997) (in press)), and a mathematical model has been constructed that accounts for this behavior (Christ, G.J., et al., *Journal of Urology* 155:620A (Abstract) (1996); Christ, G.J., et al., *FASEB J.* 9:A914 (1995)).
10 The major implication is that the presence of these gap junction channels makes it likely that only a small fraction of the corporal smooth muscle cells would need to be genetically modified to affect rather global changes in corporal smooth muscle tone.

The second major feature of the human penis that makes gene therapy an attractive possibility, is that the presence of pharmacologically induced erections
15 in many impotent men indicates that the veno-occlusive mechanism is properly functioning in many these patients. In such patients, an erection could be pharmacologically induced by conventional intracavernous agents, while simultaneously injecting the gene(s) of interest. As such, the injected gene(s) would be expected to be largely restricted to the corporal parenchyma, because the venous
20 outflow during a normal erection is very small (Carrier, et al. *J. Urol.* 42.4 (1993) 468-81; Andersson, et al. *Physiological Reviews* 75.1 (1995) 191-236; Lerner, et al. *J. Urol.* 149.5 Pt 2 (1993) 1246-55; Lue, et al. *J. Urol.* 137 (1987) 829). In this scenario, there would be little risk of systemic vascular side effects.

The method of gene therapy of the present invention was designed to
25 take advantage of the fact that relatively subtle alterations in the balance between contracting and relaxing stimuli can result in profound alterations in erectile physiology and function (Lerner, et al. *J. Urol.* 149.5 Pt 2 (1993) 1246-55; Azadzoi, et al. *J. Urol.* 148.5 (1992) 1587-91; Christ, et al. *British Journal of Pharmacology* 101.2 (1990) 375-81; Christ, G.J., *Urological Clinics of North America* 22.4 (1995)

-13-

727-745; Taub, et al. *J. Urol.* 42 (1993) 698). The goal of gene therapy is to restore a more normal balance between contracting and relaxing stimuli following expression of exogenous genes that code for physiologically relevant proteins in corporal smooth muscle. If expression of these exogenous genes can be maintained for a period of 5 weeks to months (as indicated herein the rat model), it would then permit the patient to obtain "normal" erections in the absence of any other exogenous manipulation, during this time period. Clearly this would be a major advance over all currently available therapies.

The discussion that follows outlines two specific strategies for gene therapy of erectile dysfunction. In the first case, the "sensitivity" of the smooth muscle cells will be nominally enhanced to the endogenous neuronal stimulus by transfecting the cells with the human maxi-K cDNA. In the second case, the neuronal "driving force" for erection is increased by transfecting corporal smooth muscle cells with a constitutively expressed nitric oxide synthase cDNA, bNOS. Clearly this strategy for gene therapy is explicitly dependent on both the efficacy and stability of the proposed transfection. Evidence for both is presented below.

The present invention is described in the following Experimental Details Sections which is set forth to aid in the understanding of the invention, and should not be construed to limit in any way the invention as defined in the claims which follow thereafter.

Experimental Details Section

A. Materials and Methods

1. Plasmids and genes

25 The pCMV β and pcDNA3 plasmids were purchased from Invitrogen (San Diego, CA). The human maxi K cDNA (hslo) was obtained from Dr. Salkoff (Washington University School of Medicine, St. Louis, MO)(McCobb, D. P., et al. *American Journal of Physiology* 269 (1995) H767-H777). The neuronal NOS cDNA was obtained from Dr. S. Snyder (Johns Hopkins University) and Dr. D. Bredt (Univ. 30 Calif. San Francisco)(Bredt, et al., *Nature* 351 (1991) 714-8). Both the human Maxi

-14-

K channel cDNA (approximately 3.9 kb)(McCobb, et al. American Journal of Physiology) 269 (1995) H767-H777) and neuronal NOS cDNA (Bredt/Snyder 91287795) (Bredt, et al. *Nature* 351 (1991) 714-8) were inserted into the XhoI-XbaI cloning sites of the pcDNA3 vector, where expression is driven off of the CMV promoter (Invitrogen). One hundred micrograms of plasmid DNA was suspended in 200 μ l sterile PBS containing 20% sucrose and injected into CC of anesthetized rats.

2. Gene transfer of Lac Z into the corpus cavernosa using various techniques.

Naked DNA. One hundred μ g of pCMV β plasmid (Clontech, CA) (contains the LacZ gene under the control of the CMV promoter) in 200 μ l phosphate buffered saline (containing 20% sucrose) were injected into corpus cavernosum into 3 month old Fischer rats (under anesthesia). Ten days later CC tissue was resected and stained for β -galactosidase activity.

Liposomes. Five micrograms of pCMV β plasmid in 100 μ l PBS were mixed with 100 μ l Lipofectin reagent (Gibco), and the resultant liposome complexes (200 μ l) were injected into corpus cavernosum into 3 month old Fischer rats (under anesthesia). Ten days later CC tissue was resected and stained for β -galactosidase activity.

Adenovirus Vector. Two hundred microliters of Adenovirus vectors ($> 10^{10}$ pfu/ml) containing the lacZ cDNA were obtained from Dr. Roy Chowdhury (AECOM gene therapy core) and injected intra CC in 3 month old Fischer rats (under anesthesia). Three days later CC tissue was resected and stained for β -galactosidase activity.

3. Staining for β -galactosidase activity

CC tissue was excised from rats at various times after injection, fixed with 4% paraformaldehyde/0.1% glutaraldehyde for 3 hours, and stained with X-Gal for 15 hrs. at 37°C (Vitadello, M., et al. *Human Gene Therapy* 5 (1994) 11-8).

Animal. 62 male Sprague Dwaley (Taconic Farms, Germantown, NY) 10-20 weeks old, and weighing 200-250g were used in these experiments. All rats were fed Purina lab rodent chow ad libitum and housed individually with 07.00-19.00

-15-

light cycle. Rats were divided into the groups indicated Table 1.

Table 1: Gene Transfer and Time Course Experiments

Group	Rats	Age	Gene Therapy	Method of Gene Transfer	Time Course Experiments
A	n=12	10 week	Lac Z (n=9) Control (n=3)	Adenovirus (n=3) Liposome (n=3) Naked DNA (n=3)	
B	n=24	10 week	Lac Z (n=12) Control (n=12)	Naked DNA (Sham)	2 week (n=3) 4 week (n=3) 8 week (n=3) 12 week (n=3) 2 week (n=3) 4 week (n=3) 8 week (n=3) 12 week (n=3)
C	n=20	20 week	NOS (n=12) Control (n=8)	Naked DNA (Sham control)	1 month (n=2) 2 month (n=4) 3 month (n=4) 4 month (n=2) 1 month (n=2) 2 month (n=2) 3 month (n=2) 4 month (n=2)
D	n=18	20 week	Maxi K (n=10) Control (n=8)	Naked DNA (Sham control)	1 month (n=2) 2 month (n=4) 3 month (n=2) 4 month (n=2) 1 month (n=2) 2 month (n=2) 3 month (n=2) 4 month (n=2)

10

4. Preparation of animals for *In vivo* erectile studies

Induction of anesthesia. The rats were anaesthetized by intraperitoneal injection (35 mg/kg) of sodium pentobarbital (Anpro Pharmaceuticals). Anesthesia was maintained during the course of the experimental protocol (2-3 hrs) by subsequent

-16-

injection of pentobarbital (5-10 mg/kg) every 45-60 minutes, as required for maintenance of anesthesia.

Surgical preparation and placement of pressure monitoring cannulae. Figure 3 illustrates the entire experimental procedure. Animals were placed in the supine position and the bladder and prostate were exposed through a midline abdominal incision. The inferior hypogastric plexus (i.e., the pelvic plexus or major pelvic ganglia), pelvic nerves and the cavernous nerve were identified posterolateral to the prostate on both sides, and the stainless-steel bipolar wire electrodes were placed around these structures for electrical stimulation. The penis was denuded of skin, both crura were exposed by removing part of the overlying ischiocavernous muscle. In order to monitor intracavernous pressure (ICP), a 23-gauge cannula was filled with 250U/ml of heparin solution, connected to PE-50 tubing (Intramedic, Becton Dickinson;) and inserted into the right corpus cavernosum. The tubing was then fixed to the tunica with a 7-0 Dermalon suture, to ensure stability during measurement of ICP. Another 23 gauge cannula was connected to a 1 ml syringe and inserted into left corpus cavernosum for intracavernous drug injection. Systemic arterial blood pressure (BP) was monitored via a 25-gauge cannula placed into the carotid artery.

Both pressure lines (BP) and (ICP) were connected to a pressure transducer, which was, in turn, connected via a Transducer amplifier (ETH 400 CB Sciences, Inc) to a data acquisition board (Mac Lab/ 8e7, ADI Instruments, MA). Real-time display and recording of pressure measurements was performed on a Macintosh computer (Mac Lab software V3.4). The pressure transducers and AID board were calibrated in cm of H₂O.

Neurostimulation of cavernous nerve and recording of intracavernosal pressure. Direct electrostimulation of the cavernous nerve was performed with a delicate stainless-steel bipolar hook electrode attached to the multijointed clamp. Each probe was 0.2 mm in diameter; the two poles were separated by 1 mm. Monophasic rectangular pulses were delivered by a signal generator (custom made and with built in constant current amplifier). Stimulation

-17-

parameters were as follows: frequency; 20 Hz, pulse width; 0.22 msec, duration; 1 minute. The current protocol was the application of increasing current at the following intervals: 0.5, 1, 2, 4, 6, 8 and 10 mA. The changes in intracavernous pressure and systemic blood pressure were recorded at each level of neurostimulation.

5.5. Tissue Procurement and fixation and immunohistochemistry analysis

Tissue retrieval. Following completion of the neurostimulation experiments the penises of both the gene therapy and age-matched control animals were harvested, and the distal end of the penis marked with methylene blue to ensure the proper later identification of the distal and proximal ends. All penile tissue was immediately transferred to 4% paraformaldehyde in phosphate buffer pH 7.4 for fixation for 4 hours at 20°C, and later cryoprotected in cold 30% sucrose in 0.1M phosphate buffer (PBS; at 4°C overnight or longer), pH 7.4 for immunostaining. Part of the penis of the animal was frozen in liquid nitrogen and preserved at 80°C for molecular biological studies. Briefly, the tissue was sectioned on a cryostat at 14 µm and the sections were dried onto slides and paraffin embedded. The slides were stored at -20 C° until they were stained which was usually within 2-4 weeks.

Histology. Histological examination of the sections were performed to confirm the identification of nerves and smooth muscles. Serial, slide-mounted sections were fixed in 10% formalin and stained with hematoxylin and eosin. All slide preparation specimens were viewed with Zeiss microscope.

Nitric Oxide Synthase Immunohistochemistry. Slide mounted tissue sections were deparaffinized with xylene, rehydrated in graded alcohols and blocked for endogenous peroxidase activity with 3% hydrogen peroxide. Nonspecific binding of antibodies to the specimens was blocked by incubation with 1.5% normal goat serum in phosphate-buffered saline (PBS) for 30 minutes at room temperature. The slides were then drained and incubated for one hour at room temperature with primary antibody. The antibody used was a rabbit polyclonal antibody directed against brain NOS (Transduction Laboratories, Lexington Kentucky). An antibody concentration of 1.0 µg/ml was found to be optimal for immunostaining. Antigen binding was detected by the avidin-biotin immunoperoxidase method, using the VectaStain Elite

-18-

ABC kit. The color reaction was developed with diaminobenzidine activated with hydrogen peroxide (diaminobenzidine as the chromogen) and then counterstained with hematoxylin solution. Staining was not evident in the negative control which substituted PBS for primary antibody, supporting the specificity of primary antibody 5 used in our experiment.

Statistical analysis. All statistical analyses were performed using the Stat-View 4.5 software (Abacus Concepts, Berkeley, CA). A two-tailed Student t test for unrelated samples was utilized for comparison of group means for parameters of interest between gene therapy rats (NOS or Maxi-K) and age-matched control animals. 10 All differences were considered significant at $p < 0.05$. Unless otherwise stated, all data are expressed as the mean S.E.M.

Analysis of Neurostimulation Data. Stimulus response curves were generated for neurostimulation by plotting the fractional change in corporal pressure as a function of mean systemic blood pressure (expressed as ICP/BP) for stepwise 15 increases in current (1,2,4,6,8,10 mA)(Sigma Plot Mac V5.0 Jandel Scientific, San Rafael, CA) both for control and gene therapy rats.

6. Gene transfer of Lac Z into smooth muscle cells of the rat corpus cavernosum. Gene transfer into vascular smooth muscle cells has been achieved using various techniques, such as retroviruses, adenoviruses, cationic liposomes, or 20 naked DNA transfer. To determine the efficiency of these techniques for *in vivo*, intracorporal cavernosal gene transfer, the plasmid pCMV β was injected as naked DNA or incorporated into cationic liposomes, or recombinant adenovirus containing the Lac Z cDNA (coding for β -galactosidase), each into CC tissue of three rats. All three techniques of gene transfer produced positive results, but adenoviral mediated gene 25 transfer was the most effective, as evidenced, on the whole tissue level, by the conversion of the chromogenic substrate, X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galactoside) into its blue breakdown product by the activity of β -galactosidase.

To determine the relative number and histologic type of cells expressing 30 β -galactosidase, one hundred μ g of pCMV β plasmid in 200 μ l phosphate buffered

-19-

saline (containing 20% sucrose) were injected into the CC of 3 month old Fischer rats (under anesthesia). Thirty days later, CC from injected and control rats were excised, fixed with 4% paraformaldehyde/0.1% glutaraldehyde for 3 hours, and reacted with X-Gal for 15 hrs. at 37°C, paraffin embedded and sectioned (Vitadello, M., et al. *Human Gene Therapy* 5 (1994) 11-8). As depicted in Figure 2, β -galactosidase activity is evident in a significant number of the smooth muscle cells thirty days after DNA injection.

7. Increased intracorporal pressure following injection of cDNA for neuronal NOS or potassium channel Maxi-K

The human Maxi-K channel cDNA (hSlo) (approximately 3900 nucleotides) (McCobb) and neuronal NOS cDNA (approximately 5000 nucleotides) (Bredt/Snyder 91287795) were inserted into the XhoI-XbaI cloning sites of the pcDNA3 vector, where expression is driven off of the Cytomegalovirus promoter. One hundred μ g of each plasmid, in 200 μ l phosphate buffered saline, (containing 20% sucrose) was injected into the CC of 4 month old Fischer rats (under anesthesia). Control rats were either sham operated, sham operated with an intracorporal injection of 200 μ l PBS containing 20% sucrose, or sham operated with an intracorporal injection of 200 μ l PBS containing 20% sucrose and 100 μ g pCDNA vector DNA. Basal and nerve-stimulated intracorporal pressures (ICP) were measured between 2 weeks and 4 months after injection. No significant differences were observed in intracorporal pressures within the time frame examined, and results from all animals within each group were pooled. Likewise, no significant differences were observed among the various controls, and all control data was pooled.

The data depicted in Figure 4 and Tables 2 and 3 below indicate that the injection of either the NOS or Maxi-K cDNAs significantly increased both basal and nerve-stimulated ICP. Mean basal fractional change in ICP increased from a control level of ≈ 8 (cm of H₂O) to ≈ 14 in NOS -injected rats, to ≈ 13 in Maxi K -injected rats. In a similar manner, the nerve-stimulated fractional change in ICP was approximately 30% higher in both NOS and maxi K-injected rats, over a range of 2-10 milli amp stimulation.

Table 2. Intracavernous pressure (ICP) response following nerve stimulation in NOS and control group

5		Cavernous Nerve Stimulation*							
		ICP* (Basal)	ICP* 0.5mA♥ M±SEM*	ICP 1mA M±SEM	ICP 2mA M±SEM	ICP 4mA M±SEM	ICP 6mA M±SEM	ICP 8mA M±SEM	ICP 10mA M±SEM
	NOS gene therapy (n=12)	14.62 ± .64	60.02 ± 5.9	102.50 ± 3.89	110.49 ± 4.65	113.93 ± 2.17	117.72 ± 2.80	121.26 ± 3.26	129.03 ± 5.4
10	Sham rats received vehicle only (n=8)	8.1 ± .37	45.81 ± 3.63	75.242 ± 3.59	83.93 ± 3.23	83.59 ± 4.52	85.67 ± 3.75	87.94 ± 4.45	92.23 ± 3.62
15	P value	.0001	.0085	.0001	.0001	.0001	.0001	.0001	.0003

* Cavernous nerve stimulation performed on both sides (Observation x 2 the # of rats)

♦ ICP-Intracorporal pressure in cm of H₂O

20 ♣ BCP-Basal corporal pressure in cm of H₂O before neurostimulation

♥ mA-milli Amperes of stimulus to the nerve

♠ M±SEM-Mean and standard error of the mean

Table 3. Intracavernous pressure (ICP) response following nerve stimulation in maxi-K and control group

5

10

15

	Cavernous Nerve Stimulation*							
	ICP* (Basal)	ICP* 0.5mA♥ M±SEM♠	ICP 1mA M±SEM	ICP 2mA M±SEM	ICP 4mA M±SEM	ICP 6mA M±SEM	ICP 8mA M±SEM	ICP 10mA M±SEM
maxi-K gene therapy (n=10)	13.13 ± .60	65.21 ± 3.35	99.81 ± 3.19	103.21 ± 3.05	108.12 ± 3.97	112.67 ± 3.50	115.45 ± 7.99	129.50 ± 4.83
Sham rats received vehicle only (n=8)	8.16 ± .37	45.81 ± 3.63	75.24 ± 3.59	80.99 ± 3.25	83.97 ± 3.23	85.67 ± 3.75	87.94 ± 4.45	92.23 ± 3.62
P value	.0001	.0030	.0001	.0002	.0001	.002	.0003	.0002

20 * Cavernous nerve stimulation performed on both sides (Observation x 2 the # of rats)

♦ ICP-Intracorporal pressure in cm of H₂O

♣ BCP-Basal corporal pressure in cm of H₂O before neurostimulation

♥ mA-milli Amperes of stimulus to the nerve

♠ M±SEM-Mean and standard error of the mean

25

B. Results

Potassium channels and corporal smooth muscle function: Evidence that altering K channel function can increase "sensitivity" to relaxation. Recent studies by the inventors have indicated that hyperpolarization of corporal smooth muscle cells via activation of potassium channels represents an important mechanism for controlling corporal smooth muscle tone (Holmquist, F., et al., *J. Urol.* 144 (1990) 146; Christ, G.J., et al., *Journal of Andrology* 14.5 (1993) 319-28; Fan, S.F., et al., *J. Urol.* 153 (1995) 818; Christ, G.J., *Urological Clinics of North America* 35 22.4 (1995) 727-745). This observation reflects the fact that sustained contraction of human corporal smooth muscle, which is characteristic of flaccidity (the condition the vast majority of the time) is largely dependent on continuous transmembrane Ca²⁺ flux

-22-

through voltage-gated Ca^{2+} channels. The activity of these voltage dependent calcium channels in corporal smooth muscle cells is, in turn, closely modulated by hyperpolarizing currents, initiated and carried mainly by K channels. Among the subtypes of K^+ channels, the ≈ 180 pS Ca^{2+} sensitive maxi-K channel is one of the most prominent in corporal smooth muscle cells (Fan, S.F., et al., *J. Urol.* 153 (1995) 818). Membrane hyperpolarization of corporal smooth muscle cells following activation of K channels can be accomplished by both receptor (e.g., PGE or NO^-)- and nonreceptor-mediated (e.g., NO^- or cGMP) stimuli, derived from neuronal as well as endothelial sources. These data are summarized in Figure 2 and Table 5.

10 The putative mechanism of action is thought to be as follows: release of an endogenous corporal vasorelaxant(s), for example, nitric oxide, is thought to either directly activate the K channel, or, to regulate K channel activity secondary to activation of soluble guanylate cyclase, increases in intracellular cGMP levels, activation of G kinase, and phosphorylation of cellular proteins, including
15 nonjunctional ion channels such as K and Ca^{2+} channels. Increased kinase activity (either A or G) has opposing action on Ca^{2+} and K channels, resulting in decreased activity of the former and increased activity of the latter. Thus, an elevation in intracellular NO^- and/or cGMP levels can result in both activation of K channels and inhibition of Ca^{2+} channels. The algebraic sum of these two opposing effects is to
20 significantly diminish transmembrane calcium flux, resulting in diminished corporal smooth muscle tone, and thus, corporal smooth muscle relaxation.

Since the activity of the maxi-K channel appears to be modulated by all of the physiologically relevant endogenous regulators of corporal smooth muscle tone (Figure 2), including PGE (Zhang, et al., *Journal of Urology*, 155:678A (1996);
25 Zhao, et al., *J. Urol.* 154 (1995) 1571-1579; Zhao, et al., *Journal of Urology*, 155:678A (1996) as well as NO^- (Christ, et al., unpublished observations), it is clearly an important final common mediator of the degree of corporal smooth muscle tone. Consistent with this hypothesis, the inventors have preliminary evidence that altered regulation/function of this channel may represent an important feature of the presence
30 of organic erectile dysfunction per se, in human corporal smooth muscle (Fan, S.F.,

-23-

et al., *J. Urol.* 153 (1995) 818; Christ, G.J., *Urologic Clinics of North America*, 22.4:727-745 (1995); Christ, G.J., et al., *Journal of Urology*, 155:620A (1996)). For all of these reasons, the inventors feel that the relatively stable transfection of corporal smooth muscle cells with the human smooth muscle maxi-K channel cDNA 5 represents an important and attractive strategy for modulating erectile capacity.

Nitric oxide and corporal smooth muscle function: Evidence that increasing the amount of NO⁻ expressed in corporal tissue can increase the "driving force" for relaxation. An abundance of recent experimental evidence documents the important 10 role played by nitric oxide (NO⁻) in arterial and corporal smooth muscle relaxation, and thus, penile erection (Argiolas, et al., *Neuropharmacology* 33.11 (1994) 1339-44; Burnett, et al., *Science* 257.5068 (1992) 401-3; Trigo-Rocha, et al., *J. of Physiology* 264.2 Pt 2 (1993) H419-22; Burnett, et al. *Biology of Reproduction* 52.3 (1995) 485-9). For example, electrical stimulation of both human (Saenz de Tejada, et al., *New 15 England Journal of Medicine* 320.16 (1989) 1025-30) and rabbit (Ignarro, et al., *Biochem Biophys Res Commun* 170 (1990) 843-850) corpus cavernosal muscle strips results in smooth muscle relaxation. These responses are thought to be mediated via release of nitric oxide. Consistent with this supposition, these relaxation responses can inhibited by nitroglycerin-substituted analogs of L-arginine, which block NO⁻ 20 formation (Ignarro, et al., *Biochem Biophys Res Commun* 170 (1990) 843-850; Holmquist, et al., *Acta Physiol Scand* 141 (1991) 441-442; Kim, et al., *J. Clin. Invest.* 88 (1991) 112-118). Further, the relaxation of both rabbit and human corporeal smooth muscle can be induced through compounds that release NO⁻ (Ignarro, et al., *Biochem Biophys Res Commun* 170 (1990) 843-850; Rajfer, et al., 25 *New England Journal of Medicine* 326 (1992) 90-94; Christ, G.J., et al. *Urological Clinics of North America* 22.4 (1995) 727-745). Moreover, the importance of the NO⁻ dependent pathway for relaxation of human corporal smooth muscle has also been documented (Bush, et al., *J. Urol.* 147 (1992) 1650-1655; Trigo-Rocha, et al., *Neurology & Urodynamics* 13.1 (1994) 71-80; Christ, et al., *Canadian Journal of*

-24-

Physiology and Pharmacology, 73:714-726 (1995)).

Nitric oxide is produced by the enzyme nitric oxide synthase (NOS) as a product of the enzymatic conversion of L-arginine to L-citrulline. NO[•] is produced in endothelial cells upon cholinergic stimulation or by neuronal sources (released from 5 NANC nerve terminals). With respect to the latter, NO[•] is a novel neurotransmitter in that it is not stored in synaptic vesicles in nerve terminals but is synthesized on demand. Biochemical and histochemical evidence in rabbit and rat penis suggests that the NOS isozyme which functions in penile erection belongs to the cNOS type (Burnett, et al., *Science* 257.5068 (1992) 401-3). A neural source for NOS in the rat 10 penis was demonstrated by Keast (Keast, J.R., *Neurosciences Letter* 143 (1992) 69-73; Burnett, et al., *J. Urol.* 150.1 (1993) 73-6; Burnett, et al., *Science* 257.5068 (1992) 401-3) localizing NOS to the autonomic nerves of rat and human penis by both immunohistochemistry with rat cNOS antibody and by NADPH diaphorase histochemistry. The mechanism of action of NO[•] is thought to be as follows: after 15 production, NO[•], a highly lipophilic substance, quickly diffuses (in three dimensions (Christ, et al., *Biophysical Journal* 67:1335-1344 (1994)) into corporal smooth muscle cells, where it results in activation of soluble guanylate cyclase, catalyzing the conversion of GTP to cGMP. This increase in cGMP activates protein kinase G, which, as illustrated in Figure 2, leads to decreases in intracellular Ca²⁺, producing 20 corporal smooth muscle relaxation (Moncada, S., *Acta Physiol Scand* 145 (1992) 201-227). As mentioned above, there is also recent evidence that in at least some vascular smooth muscle cells, NO[•] may directly interact with K channels to elicit hyperpolarization and smooth muscle relaxation.

In the flaccid state NOS activity is thought to be minimal (Ignarro, et 25 al., *Biochem Biophys Res Commun* 170 (1990) 843-850; Rajfer, et al., *New England Journal of Medicine* 326 (1992) 90-94; Azadozi, et al., *J. Urol.* 147.1 (1992) 220-225; Brock, et al., *Urology* 42.3 (1993) 412-417; Hellstrom, et al., *J. Urol.* 151.6 (1994) 1723-7; Pickard, et al., *British Journal of Urology* 75.4 (1995) 516-22; Carrier, et al., *J. Urol.* 153.5 (1995) 1722-7; Garban, et al., *American Journal of*

-25-

Physiology (1995) H467-H475; Burnett, et al., *Biology of Reproduction* 52.3 (1995) 485-9). The intensity of the histochemical detection of NADPH diaphorase in cavernosal tissue has been shown to be decreased in patients with cavernosal nerve injury, implying decreased NOS activity (Brock, et al., *Urology* 42.3 (1993) 412-417).

5 Furthermore, it has been suggested that the impaired relaxation responses (to electric field stimulation) of the cavernosal nerve of diabetic men may also be due to decreased NOS production (Saenz de Tejada, I., *New England Journal of Medicine* 320.16 (1989) 1025-30; Taub, et al., *Urology* 42 (1993) 698; Christ, G.J., *Urologic Clinics of North America* 4 22.4 (1995) 727-745; Vernet, et al., *Endocrinology* 136

10 (1995) 5709-5717). Thus, the introduction of a constitutively expressed cDNA for nitric oxide synthase might be expected to result in corporal smooth muscle relaxation and greater resting and nerve-stimulated pressure responses. As described below, the cDNA for neuronal NOS has been inserted into the corpus cavernosa of rats and a statistically significant, and physiologically relevant alteration was observed in the

15 intracavernous pressure response to electrical stimulation of the cavernous nerve (Table 2).

Selection of Rat model. Rat was selected for the gene therapy studies, as the rat penis has been shown to be histologically and pharmacologically similar to human penis (Lesson, et al., *Investigative Urology* 3.2 (1965) 144-145). Among

20 many known models, the rat is excellent for the study of penile erection (Lesson, et al., *Investigative Urology* 3.2 (1965) 144-145; Quinlan, et al., *J. Urol.* 141.3 (1989) 656-61; Chen, et al., *J. Urol.* 147 (1992) 1124-1128; Martinez-Pineiro, et al., *European Urology*, 25 (1994) 62-70) neurogenic and diabetic impotence (Rehman, et al., *Am J Physiol* (1997) in press).

25

MAXI-K CHANNEL RESULTS:

Evidence that K Channels Modulate Corporal Smooth Muscle Relaxation: The putative role of the maxi-K channel in mediating NTG- and PGE₁-induced relaxation responses in the human corpora. Evidence from both cellular

-26-

and isolated tissue studies documents the important role of the maxi-K channel in modulating relaxation responses in this tissue.

NTG & maxi-K: As illustrated by the representative example in Figure 1, in addition to the aforementioned effects on PE-induced contractile responses, selective blockade of the maxi-K channel with 1 mM TEA also results in a significant attenuation of the NTG-induced relaxation response (100 nM). Studies on five other corporal tissue strips revealed that the mean \pm S.E.M. %relaxation response elicited by 100 nM NTG was of $20.3 \pm 3.2\%$; compare this value with the expected value of 50.1%, as determined in another recent publication. This finding documents that activation of the maxi-K channel is also likely to be an important component of the NTG-induced relaxation response. Consistent with this hypothesis, preliminary patch clamp studies cells (i.e., attached patch recording mode) on cultured corporal smooth muscle cells, with albeit much greater NTG concentrations (100 μ M), demonstrated an NTG-induced increase in maxi-K channel activity to cultured corporal smooth muscle.

PGE₁ & maxi-K: Recent electrophysiological studies utilizing all four recording modes documented that PGE₁ causes a concentration-dependent increase in the activity of the maxi-K channel; over the same concentration range as we observe cAMP formation in cultured cells and relaxation of precontracted isolated human corporal smooth muscle strips (Zhang, et al., *J. Urol.* 155:678A (1996)). In addition, this increase in maxi-K channel activity is correlated with significant alterations in the ET-1-induced intracellular calcium transient seen in fura-2 loaded cultured corporal smooth muscle cells. Specifically, preincubation of cultured human corporal smooth muscle cells with 500 nM PGE₁ resulted in a significant $\approx 40\%$ decrease in the peak amplitude of the ET-1-induced (50 nM) calcium transient above baseline (i.e., ≈ 70 nM) from a control value of 161.5 ± 19.5 nM to 102.6 ± 9.5 nM (Zhao, et al., *J. Urol.* 155:678A (1996)). Note that this decrease is indistinguishable from the decrease seen in absence of extracellular Ca²⁺ (2 mM EGTA) or when cells are preincubated with nifedipine (Zhao & Christ, *J. Urol.* 154:1571-1579 (1995)) (or

-27-

verapamil (Christ et al., unpublished observations); both of which are blockers of the L-type voltage-dependent calcium channel).

5 **Table 4. Summary of Documented *in vitro* effects of the maxi-K channel on the physiology of corporal smooth muscle**

	PE-induced contraction increased	Resting corporal smooth muscle tone increased	Resting intracellular calcium levels decreased	ET-1-induced calcium response decreased	Relaxation response decreased	Channel Activity increased
10	YES (1 mM TEA)	YES (10-100 mM TEA)	YES transfection with (hSlo cDNA)	YES transfection with (hSlo cDNA) or preincubation with PGE ₁ (500 nM)	YES (1 mM TEA)	YES 100 μ M NTG or 30 nM-30 μ M PGE ₁

Finally, it is herein shown (Table 6) that transfection of cultured human corporal smooth muscle cells with the human smooth muscle maxi-K cDNA, hSlo, results in a significant decrease ($\approx 25\%$) in the mean resting intracellular calcium levels, as well as a decrease ($\approx 45\%$) in the peak amplitude of the ET-1-induced intracellular calcium transient. While the physiological significance of the former observation is uncertain, note, that the effects of transfection on the ET-1-induced intracellular calcium transient (Table 5), are remarkably similar to those seen in the presence of PGE₁, nifedipine and verapamil, or in the absence of extracellular calcium. Taken together, all of these data are totally consistent with the hypothesis that increased maxi-K channel activity, following either the presence of a greater number of maxi-K channels (presumably the effect of the transfection, although this has not yet been unequivocally established), or following cellular activation with, for example, PGE₁, is associated with cellular hyperpolarization, decreased transmembrane calcium flux through L-type voltage-dependent calcium channels, and a corresponding decrease in the peak amplitude of the ET-1-induced calcium transient. Moreover, since the peak amplitude of the intracellular calcium transient measured on

-28-

cultured corporal smooth muscle cells accurately tracks the magnitude of the steady-state contractile response measured on isolated corporal tissue strips (Christ, et al., *J. Urol.* 153:1998-2003 (1995)), these data provide compelling evidence that the increased activity of the maxi-K channel modulates the magnitude of the corporal smooth muscle contractile response, at least in part, by altering transmembrane calcium flux. It is important to point out that the dual role of the maxi-K channel in modulating both the magnitude of contraction and relaxation takes advantage of the fact that maxi-K-induced inhibition of transmembrane calcium flux can occur following agonist (PE or ET-1)-induced increases in intracellular calcium, or following PGE₁- (presumably PKA) or NTG-induced (presumably PKG) increases in phosphorylation of the maxi-K channel; these ideas are consistent with the literature in other vascular smooth muscle cell types (*see* Table 5, below, and Figure 2).

Table 5. Effects of vasoactive compounds on ion channel activity, membrane potential and corporal smooth muscle tone

5

10

15

Membrane Potential -30mV (DEPOLARIZED; i.e., Contracted)			
Agonist	Channel Type Affected	Putative Mechanism	Effect on Smooth Muscle Tone
ET-1	L-type Ca^{2+} increases	voltage or phosphorylation	increased tone
PE	K_{Ca} increases	Ca^{2+} -sensitive	modulates increase in tone
KCl	K_{ATP} increases	decreased ATP	modulates increase in tone
TEA	K_{Ca} decreases	channel blockade	increased tone
Glibenclamide	K_{ATP} decreases	channel blockade	increased tone
↑ -40 to -50 mV (RESTING POTENTIAL) ↓			
PGE_1	K_{Ca} increases	phosphorylation	decreased tone
NTG	L-type Ca^{2+} decreases	voltage or phosphorylation	decreased tone
PINACIDIL	K_{ATP} increases	increased mean open time	decreased tone
Membrane Potential -60 mV (HYPERPOLARIZED; i.e., Relaxed)			

Table 6. Effect of transfection with hSlo cDNA on resting and ET-1-induced changes in Ca_i .

5	Control Cells (n=17)		TT Transfected Cells (n=32)	
	Resting Ca_i	ET-1 (50 nM)	Resting Ca_i	ET-1 (50 nM)
	74.7±4.0 nM	164.1±17.8 nM	*56.7±2.5 nM	*90.8±6.6 nM

* -denotes a statistically significant difference from control values; $p < 0.001$, Student's
 10 t test for unpaired samples. Ca_i refers to the intracellular calcium concentrations.
 The values given for the ET-1 induced increase represent the peak amplitude of the
 intracellular calcium transient as described in Zhao & Christ, *J. Urol.* 154 (1995)
 1571-1579.

As a first test of the potential utility of modulating K channel activity to the therapy of erectile dysfunction, preliminary studies were conducted on a rat model *in vivo*. Briefly, it was found that injection of naked cDNA encoding the human smooth muscle maxi-K channel (i.e., hSlo; obtained from Dr. Salkoff, Washington University), into the rat corpora, resulted in significant uptake and gene expression. This was documented by the fact that the nerve-stimulated intracavernous pressure increases observed on 8 month old Sprague-Dawley rats injected with the maxi-K cDNA were significantly greater than the intracavernous pressure responses seen in age-matched control, sham-operated animals (Figure 3 and Table 5). Moreover, the incorporation of this gene (again, as judged by the significant elevation of intracavernous pressure relative to control animals) remained stable for more than three months. These *in vivo* studies are entirely consistent with all of the *in vitro* observations made by the inventors, and thus, further document the importance of K channels to the modulation of corporal smooth muscle tone. Finally, although it is recognized that there may be other subunits of the human smooth muscle maxi-K channel in human corporal tissue (L. Salkoff, personal communication), these studies represent a reasonable starting point for evaluating the role of the maxi-K channel to

-31-

erectile physiology. In summary, these studies appear to provide hope that, after obtaining a more detailed understanding of how K channels modulate smooth muscle tone in a diverse patient population, one might use the powerful tools of molecular genetics to more precisely alter the balance between contraction and relaxation; such that men would be able to more consistently obtain rigid erections on their own, without the necessity of resorting to any of the limitations associated with current therapeutic regimens.

-32-

What is claimed is:

1. A method of gene transfer into a smooth muscle cell comprising the step of introducing into the cell a DNA sequence encoding a protein involved in the regulation of smooth muscle tone.
2. The method of Claim 1 wherein the cell is a corporal or an arterial cell.
3. The method of Claim 1 wherein the protein modulates vasorelaxation.
4. The method of Claim 3 wherein the protein is selected from the group consisting of nitric oxide synthase, guanylate cyclase, adenylate cyclase, protein kinase G, protein kinase A, potassium channels, calcium channels, and any combination thereof.
5. The method of Claim 1 wherein the protein encoded by the DNA inhibits a protein that modulates vasoconstriction of smooth muscle.
6. The method of Claim 5 wherein the protein that modulates vasoconstriction of smooth muscle is protein kinase C.
7. The method of Claim 1 wherein the DNA sequence is introduced by a method selected from the group consisting of electroporation, DEAE Dextran, cationic liposome fusion, protoplast fusion, DNA coated microprojectile bombardment, injection with recombinant replication-defective viruses, homologous recombination, and naked DNA transfer.
8. The method of Claim 1 wherein the DNA sequence is genomic DNA or cDNA.

-33-

9. A method of inducing penile erection in a subject comprising the introduction and expression of a DNA sequence encoding a protein involved in the regulation of smooth muscle tone into a sufficient number of cells of the subject to induce penile erection in the subject.
10. The method of Claim 9 wherein the cell is a corporal or an arterial cell.
11. The method of Claim 9 wherein the protein modulates vasorelaxation.
12. The method of Claim 11 wherein the protein is selected from the group consisting of nitric oxide synthase, guanylate cyclase, adenylate cyclase, protein kinase G, protein kinase A, potassium channels, calcium channels, and any combination thereof.
13. The method of Claim 9 wherein the protein encoded by the DNA inhibits a protein that modulates vasoconstriction of smooth muscle.
14. The method of Claim 13 wherein the protein that modulates vasoconstriction of smooth muscle is protein kinase C.
15. The method of Claim 9, wherein the subject has erectile dysfunction.
16. The method of Claim 15, wherein said erectile dysfunction results from incomplete relaxation of smooth muscle.
17. The method of Claim 15, wherein said erectile dysfunction results from neurogenic dysfunction.
18. The method of Claim 15, wherein said erectile dysfunction results from arteriogenic dysfunction.

-34-

19. The method of Claim 15, wherein said erectile dysfunction results from veno-occlusive dysfunction.

20. The method of Claim 9 wherein the DNA sequence is introduced by a method selected from the group consisting of electroporation, DEAE Dextran, cationic liposome fusion, protoplast fusion, by creation of an *in vivo* electrical field, DNA coated microprojectile bombardment, injection with recombinant replication-defective viruses, homologous recombination, and naked DNA transfer.

21. The method of Claim 9 wherein the DNA sequence is genomic DNA or cDNA.

22. A recombinant vector comprising:

a) the DNA of or corresponding to at least a portion of the genome of a virus which portion is capable of directing the expression of a DNA sequence; and

b) a DNA sequence encoding a protein involved in the regulation of smooth muscle tone operably linked to the viral DNA and capable of expression in a target cell.

23. The recombinant vector of Claim 22 wherein the protein modulates vasorelaxation.

24. The recombinant vector of Claim 23 wherein the protein is selected from the group consisting of nitric oxide synthase, guanylate cyclase, adenylate cyclase, protein kinase G, protein kinase A, potassium channels, calcium channels, and any combination thereof.

25. The recombinant vector of Claim 22 wherein the protein encoded by the DNA inhibits a protein that modulates vasoconstriction of smooth muscle.

-35-

26. The recombinant vector of Claim 25 wherein the protein that modulates vasoconstriction of smooth muscle is protein kinase C.

27. The recombinant vector of Claim 22 wherein the virus is selected from the group consisting of a retrovirus, adenovirus, RNA virus, or DNA virus.

28. A smooth muscle cell which expresses one or more exogenous DNA sequences that encode a protein involved in the regulation of smooth muscle tone.

29. The cell of Claim 1 which is an arterial or a corporal smooth muscle cell.

30. The cell of Claim 29 wherein the protein expressed by the smooth muscle cell modulates vasorelaxation.

31. The cell of Claim 30 wherein the protein is selected from the group consisting of nitric oxide synthase, guanylate cyclase, adenylate cyclase, protein kinase G, protein kinase A, potassium channels, calcium channels, and any combination thereof.

32. The cell of Claim 29 wherein the protein encoded by the DNA inhibits a protein that modulates vasoconstriction of smooth muscle.

33. The cell of Claim 32 wherein the protein that modulates vasoconstriction of corporal smooth muscle is protein kinase C.

-36-

34. The cell of Claim 29 wherein the DNA sequence is introduced into the cell by a method selected from the group consisting of electroporation, DEAE Dextran, cationic liposome fusion, protoplast fusion, by creation of an *in vivo* electrical field DNA coated microprojectile bombardment, injection with recombinant replication-defective viruses, homologous recombination, and naked DNA transfer.

35. The cell of Claim 29 wherein the DNA expressed is genomic DNA or cDNA.

1/5




FIG. 1




FIG. 2

Inside cell:
 $[Ca^{2+}] = 100 \text{ nM}$
 $[K^+] = 150 \text{ nM}$

Outside cell:
 $[Ca^{2+}] = 2.0 \text{ mM}$
 $[K^+] = 5 \text{ mM}$

3/ 5






FIG. 3



Neurostimulation (m Amp)

FIG. 4



Factors that modulate
Vasorelaxation

Factors that modulate
Vasoconstriction

FIG. 5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/02249

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 9/12, 15/00; A01N 43/04; C07H 21/02

US CL : 514/44, 645; 435/194, 320.1; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/44, 645; 435/194, 320.1; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN; MEDLINE, EMBASE, SCISEARCH, BIOSIS, WPIDS, CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,594,032 A [GONZALEZ-CADAVID et al] 14 January 1997, see entire document.	1-5, 7-13, 15-25, 27-32
X	US 5,214,030 A [STIEF] 25 May 1993, see entire document.	1-5, 7-13, 15-25, 27-32
X	US 5,324,651 A [ONO et al] 28 January 1994, see entire document.	22-35
----		-----
Y		1-21
X	US 5,219,748 A [YOSHITAKA et al] 15 June 1993, see entire document.	22-35
----		-----
Y		1-21

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

03 APRIL 1998

Date of mailing of the international search report

28 MAY 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ANDREW WANG

Telephone No. (703) 308-0196